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reperfusion-induced renal fibrosis via the PI3K/
Akt/FoxO3a pathway
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Abstract 
Renal fibrosis is a main cause of end-stage renal disease. Clinically, there is no beneficial treatment that can effec-
tively reverse the progressive loss of renal function. We recently synthesized a novel proteolysis-resistant cyclic helix 
B peptide (CHBP) that exhibits promising renoprotective effects. In this study, we evaluated the effect of CHBP on 
renal fibrosis in an in vivo ischemia reperfusion injury (IRI) model and in vitro TGF-β-stimulated tubular epithelial cells 
(TCMK-1 and HK-2) model. In the IRI in vivo model, mice were randomly divided into sham (sham operation), IR and 
IR + CHBP groups (n = 6). CHBP (8 nmol/kg) was administered intraperitoneally at the onset of reperfusion, and renal 
fibrosis was evaluated at 12 weeks post-reperfusion. Our results showed that CHBP markedly attenuated the IRI-
induced deposition of collagen I and vimentin. In the in vitro model, CHBP reversed the TGF-β-induced down-regula-
tion of E-cadherin and up-regulation of α-SMA and vimentin. Furthermore, CHBP inhibited the phosphorylation of Akt 
and Forkhead box O 3a (FoxO3a), whose anti-fibrotic effect could be reversed by the 3-phosphoinositide-dependent 
kinase-1 (PI3K) inhibitor wortmannin as well as FoxO3a siRNA. These findings demonstrate that CHBP attenuates renal 
fibrosis and the epithelial-mesenchymal transition of tubular cells, possibly through suppression of the PI3K/Akt path-
way and thereby the inhibition FoxO3a activity.
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Background
Acute kidney injury (AKI) is a common clinical syn-
drome that increases the risk of adverse outcomes. AKI 
affects >5 % of all inpatients and is especially common in 
critically ill patients. More than 36 % of patients experi-
ence AKI 1 day after admission to an intensive-care unit 
under a sepsis condition, and the prevalence increases 
to >60  % while in the intensive-care unit [1]. AKI sig-
nificantly increases the risk of chronic renal disease, end-
stage renal disease, and death, presenting a major burden 
to patients and the health care system [2]. Renal ischemia 
reperfusion injury (IRI) is one of the major causes of AKI 
[3].
Studies have shown that AKI results in incomplete 
tubular repair, which is characterized by failed differen-
tiation and persistently high signaling activity. IRI of the 
kidney is a well-established cause of renal fibrosis [4, 5]. 
Factors such as sustained innate immune cell activation, 
endothelial cell dysfunction, hypoxia, and chronic micro-
vascular injury have all been implicated in the maladap-
tive response that results in fibrogenesis and progression 
to chronic kidney disease [6]. The epithelial-mesenchy-
mal transition (EMT) plays a critical role in the patho-
genesis of fibrosis, in which renal tubular epithelial cells 
(TECs) under pathological conditions can phenotypically 
convert to a fibroblast-like morphology in the tubuloint-
erstitium [7, 8].
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Forkhead box O (FoxO) transcription factors are the 
human homologues of C. elegans transcription fac-
tor DAF-16 and share a highly conserved 110-amino 
acid DNA-binding domain termed the forkhead box or 
winged-helix domain [9]. Four principal members of the 
mammalian FoxO subfamily, FoxO1, FoxO3a, FoxO4 and 
FoxO6, have been described [10]. Among these, FoxO3a 
has been extensively studied as a crucial protein involved 
in the regulation of several essential cellular functions. 
The potency of FoxO3a is carefully regulated by phos-
phorylation. Activated 3-phosphoinositide-dependent 
kinase-1 (PI3K) activates serine/threonine protein kinase 
B (Akt) by recruiting and phosphorylating its lipid sub-
strates [11]. Akt then phosphorylates and inactivates 
FoxO3a, which results in the retention of FoxO3a in the 
cytoplasm and subsequent inhibition of target gene tran-
scription. By contrast, FoxO3a dephosphorylation results 
in its nuclear translocation and activation [11].
Recently, we used a novel cyclization strategy to syn-
thesize thioether cyclic helix B peptide (CHBP), which 
showed significantly improved metabolic stability and 
renoprotective effects [12]. In our previous studies in 
murine IRI models, CHBP exhibited a strong renoprotec-
tion effect against IRI in terms of reduced inflammation 
and apoptosis [12]. In porcine models, CHBP adminis-
tered using preservation solution and autologous blood 
perfusate provided significant protection against kidney 
IRI by increasing renal blood flow and oxygenation and 
reducing apoptosis, inflammation, as well as tissue struc-
tural damage [13]. Based on these results, we hypothesized 
that CHBP might attenuate IRI-induced renal fibrosis.
In the present study, we investigated the anti-fibrotic 
potential of CHBP in a murine renal IRI-induced fibro-
sis model and in cultured proximal tubular epithelial cells 
(TECs). We also examined the molecular mechanisms of 
CHBP-mediated renoprotection against fibrosis.
Methods
Renal IRI in vivo model
Male BALB/c mice (20–25 g) were obtained from Shang-
hai Slac Lab Animal, Co., Ltd., and bred in an SPF-grade 
experimental animal room. The renal IRI model was 
established as previously described [12, 14]. Each mouse 
was anesthetized intraperitoneally with pentobarbital at 
0.1  g/kg. The core body temperature was maintained at 
37  °C using a homeothermic pad during the entire pro-
cedure. The abdominal cavity was exposed by a mid-
line incision. Both kidneys were exposed, and the renal 
pedicles were carefully isolated. Bilateral renal occlusion 
was performed for 30  min using non-traumatic vascu-
lar clamps. Occlusion was confirmed by monitoring the 
transformation in renal tissue color from red to navy 
blue. After the clamps were removed, the kidneys were 
observed for an additional 5 min to ensure that the color 
returned, which indicated blood reperfusion. Subse-
quently, 1  ml of saline solution at 37  °C was applied to 
the abdomen, and the incision was sutured in two layers. 
For the sham group, both kidneys were exposed, and the 
renal pedicles were carefully isolated without occlusion. 
All animal experiments were performed according to the 
guidelines of the Care and Use of Laboratory Animals 
of the Laboratory Animal Ethical Commission of Fudan 
University with good animal surgical research practices 
and was approved by the Animal Ethical Committee of 
Zhongshan Hospital, Fudan University.
Immediately after the mice were sutured, they were 
randomly divided into three groups (n  =  6) accord-
ing to the different treatments: (1) Sham group (with-
out renal pedicles occlusion); (2) IR group (with renal 
pedicles occlusion); (3) CHBP group (with renal pedi-
cles occlusion and CHBP administration). The IR group 
received PBS and the CHBP group received PBS contain-
ing 8  nmol/kg CHBP by intraperitoneal injection at the 
onset of reperfusion. Animals were ethically sacrificed at 
12 weeks post-reperfusion.
TECs EMT in vitro model
TCMK-1 and HK-2 cells were purchased from the Ameri-
can Type Culture Collection (ATCC) and cultured in 
DMEM/F12 medium containing 10  % FBS. Cells were 
grown in a humidified incubator at 37  °C with 5  % CO2 
and 95  % air. TCMK-1 and HK-2 cells were seeded into 
6-well plates (1  ×  105 cells/well) and cultured for 24  h. 
In the initial in  vitro experiment, cells were divided into 
4 groups: a control (no TGF-β added) and three groups 
receiving TGF-β (2.5, 5 or 10  ng/ml). Cells were har-
vested and processed for western blot analysis at 72  h 
after the addition of TGF-β to the appropriate wells. 
In the second experiment, TCMK-1 and HK-2 cells 
were divided into 5 groups: a control group, a TGF-β 
(5  ng/ml) group, and three TGF-β  +  CHBP (0.1, 1 or 
10  μM) groups. 72  h after the addition of TGF-β and/
or CHBP to the wells, cells were harvested and pro-
cessed for western blot analysis. In the third experi-
ment, all wells received the same levels of TGF-β (5  ng/
ml) and CHBP (10 μM). The wells (HK-2 cells only) were 
divided into 7 groups: (1) normal (no TGF-β); (2) TGF-β; 
(3) TGF-β +  CHBP; (4) TGF-β +  CHBP +  wortmannin 
(0.1 μM); (5) TGF-β + CHBP + FoxO3a siRNA (0.1 μM); 
(6) TGF-β  +  CHBP  +  control siRNA (0.1  μM); and (7) 
TGF-β + CHBP + wortmannin (0.1 μM) + FoxO3a siRNA 
(0.1 μM). In each experiment, cells were cultured for 72 h 
and then harvested and processed for western blot analy-
sis. The efficacy of FoxO3a siRNA (Additional file 1: Figure 
S1a, b) and wortmannin was tested (Additional file 1: Fig-
ure S1c). All experiments were performed in triplicate.
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Histological assessment
Hematoxylin and eosin (H&E) staining was performed 
to assess histological injury. The tissue sections were 
blind-labeled and reviewed by two renal pathologists. 
Renal damage was graded based on the percentage 
of damaged tubules in the sample: 0 =  normal kidney 
(no damage); 1  =  minimal damage (<25  % damage); 
2  =  mild damage (25–50  % damage); 3  =  moderate 
damage (50–75  % damage); and 4  =  severe damage 
(>75 % damage) similar with previous descriptions [3]. 
Injury included cell vacuolization, cell necrosis and 
interstitial infiltration. Scores of 1 or 2 represent mild 
injury, and scores of 3 or 4 and 5 or 6 represent moder-
ate and severe injuries, respectively.
Extracellular matrix deposition assay
The deposition of extracellular matrix was evaluated 
using Masson trichrome and Sirius red (collagen-spe-
cific dye) staining as previously described [5]. Image-
Pro Plus 6.0 software was used to quantify the level of 
fibrosis.
Immunohistochemistry
Immunohistochemical staining of vimentin and collagen 
I (Abcam, Cambridge, UK) was performed on frozen kid-
ney sections using a DAKO ChemMate EnVision Detec-
tion Kit (DAKO, Carpinteria, CA, USA) as previously 
described [15–17].
Western blot analysis
Membrane proteins were separated on SDS–poly-
acrylamide gels and transferred to polyvinylidene dif-
luoride membranes. The membranes were blocked 
with 5  % milk and incubated overnight with anti-E-
cadherin, anti-α-SMA, anti-vimentin, anti-PI3K p85, 
anti-p-Akt Ser473, anti-p-Akt Th308, anti-Akt, anti-
p-FoxO3a Ser253, anti-p-FoxO3a Ser318/321, anti-
FoxO3a (Cell Signaling, Beverly, MA, USA, 1:1000), 
or anti-tubulin (Abcam, Cambridge, UK, 1:10,000) 
antibodies. The results were analyzed as previously 
described [15].
Statistical analysis
Data are presented as the mean  ±  standard devia-
tion. Statistical analysis (SPSS 18.0 software, SPSS Inc., 
Armonk, NY, USA) was performed using the two-tailed 
independent Student’s t test after a demonstration of 
homogeneity of variance with the F test or one-way 
ANOVA for more than two groups. The Scheffe test was 
used for post hoc analysis. Statistical significance was set 
as p < 0.05.
Results
CHBP attenuates renal IRI‑induced tissue injury, fibrosis 
and collagen deposition
To evaluate the renoprotective effects of CHBP in the 
murine renal IRI model, we performed H&E staining of 
the kidneys in each group at 12  weeks post-reperfusion 
(Fig.  1a). Semi-quantitative analysis using a histologi-
cal scoring system revealed that the kidney tissue in the 
CHBP-treated group was well protected, showing mild 
interstitial edema and cellular infiltration. Severe intersti-
tial edema and cellular infiltration with tubular epithelial 
cell vacuolation were found in the IR group (Fig. 1d).
Masson trichrome staining was used to demonstrate 
extracellular matrix (ECM) deposition within the tubu-
lointerstitium (Fig. 1b), and ECM deposition was evalu-
ated by Sirius red staining, which intercalates tertiary 
grooves in the structures of collagen I and III (Fig.  1c). 
Both stains indicated that renal fibrosis and collagen 
deposition were elevated in the IR group but markedly 
reduced by CHBP treatment (Fig. 1e, f ).
CHBP decreases vimentin and collagen I expression in IRI 
kidneys
Next, we determined the effect of CHBP on the expres-
sion of myofibroblast activation marker vimentin. Immu-
nofluorescence (IF) analysis showed that the expression 
of vimentin was increased in the IR group compared 
with the sham group, suggesting that myofibroblast acti-
vation was stimulated by IRI. However, treatment with 
CHBP significantly inhibited the IRI-induced up-regula-
tion of vimentin (Fig.  2a). Collagen I is the most abun-
dant collagen of the human body. It is the end product 
in tissue repair, and is present in scar tissue. IF staining 
indicated that CHBP decreased the expression of colla-
gen I (Fig. 2b) in kidneys. These results demonstrate that 
CHBP reduces myofibroblast activation and fibrosis.
TGF‑β stimulates EMT in murine and human TECs
TGF-β enhances ECM gene regulation and stimulates 
ECM protein accumulation in renal cells by increasing the 
expression of protease inhibitors [18]. To determine the 
optimal concentration of TGF-β for use in culture, we first 
tested a range of concentrations (0, 2.5, 5 and 10 ng/ml for 
72 h) in murine (Fig. 3a) and human (Fig. 3b) TECs. West-
ern blotting analysis revealed that TGF-β significantly 
increased the expression of a-SMA and vimentin while 
concomitantly inhibiting E-cadherin expression com-
pared with the control groups in both murine (Fig. 3c) and 
human (Fig.  3d) TECs. The pro-EMT effects of TGF-β 
were dependent on the concentration, and 5  ng/ml was 
identified as the optimal concentration.
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CHBP inhibits TGF‑β‑stimulated EMT in murine and human 
TECs
The expression levels of E-cadherin, vimentin and 
a-SMA, all well-known markers of EMT, were analyzed 
in murine (Fig.  4a) and human (Fig.  4b) TECs using 
5  ng/ml TGF-β. Western blotting analysis revealed that 
CHBP significantly inhibited the expression of a-SMA 
and vimentin and enhanced the expression of E-cad-
herin compared with the control groups in both murine 
(Fig. 4c) and human (Fig. 4d) TECs. The anti-EMT effects 
of CHBP were concentration-dependent.
CHBP blocks PI3K/Akt/FoxO3a signaling
To further investigate the potential mechanism of 
CHBP-mediated anti-EMT gene regulation in TECs, 
we performed western blotting analysis targeting the 
PI3K/Akt/FoxO3a pathway (Fig.  5a). CHBP significantly 
decreased the levels of phosphorylated Akt (p-Akt) 
and phosphorylated FoxO3a (p-FoxO3a) (Fig.  5c, d, 
h, i); these changes were accompanied by an increase 
in E-cadherin and decrease in α-SMA and vimentin 
(Fig. 5e–g). In combination with the PI3K inhibitor wort-
mannin, CHBP further up-regulated or down-regulated 
Fig. 1 CHBP attenuated IRI-induced renal tissue injury, fibrosis and collagen deposition. a H&E, b Masson trichrome and c Sirius red staining were 
performed on kidney sections. 12 weeks after reperfusion. d, e, f Semi-quantitative analysis for H&E, Masson trichrome and Sirius red staining, 
respectively. Data are presented as the mean ± SD, n = 6
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the EMT-associated markers, suggesting that the PI3K/
Akt pathway is involved in the anti-EMT mechanism of 
CHBP. In addition, CHBP caused a marked reduction in 
the phosphorylation of FoxO3a. The anti-EMT effects of 
CHBP were reversed by FoxO3a siRNA, as evidenced by 
decreased E-cadherin and increased α-SMA and vimen-
tin levels (Fig.  5e–g), suggesting that the modulation of 
FoxO3a phosphorylation by CHBP plays a key role in this 
Fig. 2 CHBP decreased IRI-induced vimentin and collagen I expression. Immunofluorescence staining was performed for a vimentin and b col-
lagen I
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mechanism. Additionally, FoxO3a siRNA blocked the 
anti-EMT effects induced by the combination of CHBP 
and wortmannin.
Discussion
In this study, we demonstrated for the first time that the 
novel peptide CHBP ameliorates IRI-induced renal fibro-
sis by inhibiting the EMT of TECs. The anti-EMT effect 
of CHBP is mediated by the PI3K/Akt/FoxO3a signaling 
pathway.
Renal fibrosis is the final consequence of chronic kid-
ney disease, leading to end-stage renal disease via the 
destruction of the kidney parenchyma and a progres-
sion of renal malfunctions [19]. The abnormal ECM 
that occurs during renal fibrosis results from an over-
expression of normal extracellular matrix components 
and a pathological accumulation of extracellular matrix 
components such as collagen I. The latter proteins are 
involved in the renal scarring process and are irreversibly 
deposited in renal fibrotic tissues. In the present study, 
we demonstrated that CHBP inhibits pathological extra-
cellular matrix deposition in vivo.
The mechanism of renal fibrosis is associated with TEC 
transition to a mesenchymal cell phenotype via a process 
Fig. 3 TGF-β induced EMT in murine and human TECs. TGF-β stimulation was performed in murine TCMK-1 and human HK-2 cells. After 72 h, the 
levels of E-cadherin, vimentin and α-SMA in a TCMK-1 and b human HK-2 cells with varied levels of TGF-β (0, 2.5, 5 and 10 ng/ml) were determined 
by western blotting. c, d Quantitative results presented as the mean ± SD of the optical density of each band, n = 6. *p < 0.05 compared with the 
TGF-β control group (0 ng/ml)
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known as EMT [20]. TGF-β is a well-known central 
mediator in this process [18]. In our study, both murine 
and human TECs showed dose-dependent up-regulation 
of EMT-associated proteins in response to TGF-β stim-
ulation. CHBP blocked this effect in both murine and 
human TECs, and the anti-fibrotic effect of CHBP was 
dependent on the dosage.
Akt is normally maintained in an inactivated state and 
is activated by phosphorylation at two sites (Th308 and 
Ser473) via a PI3K-dependent process. Activated p-Akt 
regulates many cellular processes, such as proliferation, 
survival, growth, metabolism and angiogenesis, via serine 
and/or threonine phosphorylation of downstream sub-
strates [21]. Growing evidence suggests that p-Akt plays 
a role in renal fibrosis and kidney dysfunction. For exam-
ple, the PI3 K inhibitor LY294002 was observed to reduce 
proliferation and ECM synthesis in fibroblasts obtained 
from rat kidney tissue after unilateral ureteral obstruction 
[22]. In addition, pharmacological down-regulation of the 
PI3K/Akt signaling pathway not only reduced the num-
ber of pro-fibrotic interstitial cells but also suppressed 
EMT-associated α-SMA expression [23]. In a recent kid-
ney transplant model, increased expression of p-Akt was 
found to correlate with allograft interstitial fibrosis [24]. 
Fig. 4 CHBP inhibited TGF-β-induced EMT in murine and human TECs. TGF-β (5 ng/ml) and CHBP (0, 0.1, 1 and 10 μM) were added to murine 
TCMK-1 and human HK-2 cells. After 72 h, E-cadherin, vimentin and α-SMA levels in a TCMK-1 cells and b HK-2 cells were determined by western 
blotting. c, d Quantitative results are presented as the mean ± SD of the optical density of each band (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 compared with the CHBP (0 μM) + TGF-β (5 ng/ml) group
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In our study, we found that the levels of p-Akt in murine 
and human TECs were significantly increased by TGF-β 
and decreased by CHBP treatment. Reduced p-Akt levels 
in the CHBP-treated TECs correlated with a lower level 
of EMT, as indicated by higher levels E-cadherin and 
lower levels of α-SMA and vimentin. In the TECs treated 
with a combination of CHBP and wortmannin (a PI3K 
inhibitor), EMT was further inhibited owing to stronger 
inhibition of Akt signaling.
Phosphorylation of FoxO3a by Akt retains FoxO3a 
in the cytoplasm, thereby inhibiting its activity [11]. 
Accordingly, CHBP was shown to decrease the levels of 
p-FoxO3a in TGF-β-treated TECs, reflecting enhanced 
activity of FoxO3a in the nucleus. Importantly, FoxO3a 
siRNA abrogated the anti-fibrotic effect of CHBP, 
whereas the negative control siRNA had no effect, indi-
cating that the CHBP-mediated reduction in EMT is 
dependent on Akt and FoxO3a. Additionally, FoxO3a 
siRNA abrogated the strong anti-fibrotic effects of CHBP 
and wortmannin in HK-2 cells, suggesting that the pro-
fibrotic effect of Akt signaling is dependent on FoxO3a 
(Fig. 6).
With continued advance in biochemistry and bio-
technology, the use of therapeutic peptides has become 
increasingly effective and popular. CHBP is a conforma-
tionally constrained cyclized peptide derived from helix B 
Fig. 5 CHBP blocked PI3 K/Akt/FoxO3a signaling. a Western blotting analysis of the PI3K/Akt/FoxO3a pathway. Quantitative results for b PI3K p85, c 
p-Akt Ser473, d p-Akt Th308, e E-cadherin, f α-SMA, g vimentin, h p-FoxO3a Ser253, and i p-FoxO3a Ser318/321 presented as the mean ± SD of the 
optical density of each band (n = 6). δp < 0.05, δδp < 0.01, δδδp < 0.001 compared with the TGF-β group. *p < 0.05, **p < 0.01, ***p < 0.001 compared 
with the TGF-β + CHBP group. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with the TGF-β + CHBP + control siRNA group
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surface peptide (HBSP). HBSP is a linear peptide derived 
from erythropoietin and has a 9-min plasma half-life, 
which restricts its clinical application in vivo [12]. Recently, 
van Rijt reported that HBSP attenuated renal fibrosis in a 
porcine kidney model with 45 min of ischemia followed by 
7 days of reperfusion [25]. Therefore, as a conformation-
ally constrained cyclized peptide with improved stability 
and renoprotective properties [12], CHBP may become a 
promising new drug for the treatment of renal fibrosis.
In conclusion, our study demonstrated that CHBP 
attenuates renal injury in an IRI murine model by pre-
venting ECM deposition and fibrosis. CHBP also inhib-
its TGF-β-induced ECM protein expression and EMT in 
both murine and human TECs. The mechanism of the 
anti-fibrotic effect of CHBP may involve the suppression 
of the PI3K/Akt pathway and subsequent inhibition of 
FoxO3a activity.
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